Zichang Liu Maosheng Yu Feng Zhao Chenfang Zhu
10.3389/fonc.2023.976415
Front Oncol
2023 Mar 16;13:976415.
anlotinib sintilimab autoimmune liver disease immune checkpoint inhibitors immune-related adverse reactions primary squamous cell carcinoma of the thyroid tyrosine kinase inhibitors
CC BY
https://pubmed.ncbi.nlm.nih.gov/37007162/
Case Reports
PMC10062477
37007162
Anlotinib combined with Sintilimab is win-win cooperation for primary squamous cell carcinoma of the thyroid: A case report and literature review
2023